Acuta Capital Partners LLC Purchases 1,600 Shares of Celcuity Inc. (NASDAQ:CELC)

Acuta Capital Partners LLC increased its position in shares of Celcuity Inc. (NASDAQ:CELC) by 3.6% in the third quarter, HoldingsChannel reports. The firm owned 46,600 shares of the company’s stock after purchasing an additional 1,600 shares during the period. Acuta Capital Partners LLC’s holdings in Celcuity were worth $695,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Celcuity by 1.0% during the first quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock worth $17,898,000 after buying an additional 7,821 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Celcuity by 7.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after purchasing an additional 1,600 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in Celcuity in the 2nd quarter valued at $888,000. Bank of New York Mellon Corp boosted its stake in Celcuity by 42.7% in the second quarter. Bank of New York Mellon Corp now owns 66,256 shares of the company’s stock worth $1,085,000 after purchasing an additional 19,811 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Celcuity by 9.9% during the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after purchasing an additional 1,500 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Down 1.5 %

Shares of NASDAQ:CELC opened at $12.85 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The stock has a market cap of $477.12 million, a price-to-earnings ratio of -4.92 and a beta of 0.76. The company has a 50 day moving average of $14.79 and a 200-day moving average of $15.79. Celcuity Inc. has a one year low of $11.51 and a one year high of $22.19.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CELC shares. Stifel Nicolaus lifted their price target on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 7th. Lifesci Capital started coverage on shares of Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $23.00 price target on shares of Celcuity in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Celcuity has a consensus rating of “Buy” and an average price target of $29.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.